Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy

Lung Cancer

Volumn 122, Issue , 2018, Pages 234-242

  Lee, Jong Seok ^a   Lee, Ki Hyeong ^b   Cho, Eun Kyung ^c   Kim, Dong Wan ^d   Kim, Sang We ^e   Kim, Joo Hang ^f   Cho, Byoung Chul ^f   Kang, Jin Hyoung ^g   Han, Ji Youn ^h   Min, Young Joo ⁱ   Park, Keunchil ^j  

^a Seoul National University Bundang Hospital   (South Korea)

^b Chungbuk National University Hospital   (South Korea)

^c Gachon University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Asan Medical Center   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g The Catholic University of Korea   (South Korea)

^h National Cancer Center   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j Sungkyunkwan University School of Medicine   (South Korea)

more..

Author keywords

Nivolumab; Non small cell lung cancer; Programmed cell death 1

Indexed keywords

NIVOLUMAB; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CANCER RECURRENCE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPOTHYROIDISM; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RHINORRHEA; SIDE EFFECT; SOUTH KOREA; SQUAMOUS CELL CARCINOMA; THORAX PAIN; TREATMENT OUTCOME; URTICARIA; VERY ELDERLY; ADVERSE DRUG REACTION; CANCER STAGING; CLINICAL TRIAL; DRUG RESISTANCE; FOLLOW UP; KOREA; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NIVOLUMAB; PLATINUM COMPOUNDS; PNEUMONIA; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85049013316     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2018.05.023     Document Type: Article

References (25)

1. Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N. Engl. J. Med 359 (2008), 1367–1380.
2. Travis, W.D., Travis, L.B., Devesa, S.S., Lung cancer. Cancer 75 (1995), 191–202.
3. Cancer Facts and Figures. 2015 Available at: http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_100100000000. (Accessed 31 January 2017).
4. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer Version 3. 2012 Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. (Accessed 14 December 2016).
5. Scagliotti, G.V., Parikh, P., von Pawel, J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26 (2008), 3543–3551.
6. Sandler, A., Gray, R., Perry, M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355 (2006), 2542–2550.
7. Gebbia, V., Gridelli, C., Verusio, C., et al. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients: the DISTAL-2 randomized trial. Lung Cancer 63 (2009), 251–258.
8. Hanna, N., Shepherd, F.A., Fossella, F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22 (2004), 1589–1597.
9. Garassino, M.C., Martelli, O., Broggini, M., et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 14 (2013), 981–988.
10. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
11. Brahmer, J.R., Drake, C.G., Wollner, I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28 (2010), 3167–3175.
12. Wang, C., Thudium, K.B., Han, M., et al. In vitro characterization of the anti-PD-1 antibody nivolumab BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2 (2014), 846–856.
13. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
14. Gettinger, S.N., Horn, L., Gandhi, L., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33 (2015), 2004–2012.
15. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
16. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
17. Yamamoto, N., Nokihara, H., Yamada, Y., et al. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest. New Drugs 35 (2017), 207–216.
18. Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2017), 320–330.
19. Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373 (2015), 1803–1813.
20. Ferris, R.L., Blumenschein, G. Jr., Fayette, J., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375 (2016), 1856–1867.
21. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
22. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2018 Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. (Accessed 31 January 2017).
23. Herbst, R.S., Baas, P., Kim, D., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
24. Rittmeyer, A., Barlesi, F., Waterkamp, D., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
25. McLaughlin, J., Han, G., Schalper, K.A., et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2 (2016), 46–54.